Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-000078
Filing Date
2026-04-29
Accepted
2026-04-29 16:28:31
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5633
  Complete submission text file 0002100119-26-000078.txt   7489
Mailing Address C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY NJ 07446
Business Address C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY NJ 07446 (201) 478-5552
ADMA BIOLOGICS, INC. (Subject) CIK: 0001368514 (see all company filings)

EIN.: 562590442 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-82025 | Film No.: 26916646
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G